Spyre Therapeutics

We're honored to sponsor Ride4IBD this year to help amplify their message and support for #IBD. Their advocacy and dedication to uplifting the voices of IBD patients serve as a powerful reminder of the importance of our work at Spyre. We're also excited to welcome Ride4IBD founder, Cory Greenberg, to our upcoming quarterly meeting next week. Check out Ride4IBD below!?

We were honored to present at TD Cowen's 45th Annual Healthcare Investor Conference in Boston. It was a great opportunity to connect with the industry and share insights into our pipeline, including the promise of our work in next-generation monotherapies and combinations. Our CEO, Cameron Turtle, provided investors with an update on progress and anticipated developments. We look forward to the continued momentum ahead.

Today, we reported full 2024 and Q4 financial results. “We are excited to be on the cusp of progressing our suite of therapeutics into a groundbreaking Phase 2 platform study in ulcerative colitis, designed to test both monotherapies and combination therapies with the potential for unified quarterly subcutaneous dosing in maintenance, as well as a first-in-mechanism Phase 2 study in rheumatoid arthritis with our TL1A," said Cameron Turtle, Spyre's Chief Executive Officer. Read more details on 2024 earnings, other business updates and forward-looking statements legend here: https://lnkd.in/en_W6pfb

Our next #InSpyred employee spotlight proudly features Aleyda Paz. ? Aleyda joined Spyre in 2023 as part of Spyre’s financial reporting team. Ever since receiving a toy cash register for her 8th birthday Aleyda knew she wanted to work in finance. In college, Aleyda majored in accounting and then went on to earn her CPA license. ? In her free time, Aleyda enjoys cooking and baking for friends. One day she dreams of becoming a professional pastry chef! ? #employees #culture

Today, we announced our poster presentation at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO). We are excited to share preclinical findings supporting the combination potential for our SPY120 program, demonstrating superior preclinical efficacy relative to monotherapies and supporting the potential for quarterly or twice-annual dosing in humans. For more information, you can read the full news release and forward-looking statement legend here: https://lnkd.in/gGj92Tk8 The poster can be viewed during the ECCO Congress with full details via the ECCO program here: https://lnkd.in/eQNqSNCQ #IBD #BioTech

Our CEO, Cameron Turtle, recently spoke with Nimish Shah on the #RunningThroughWalls podcast to discuss building Spyre and its ambitions for 2025. Listen below.

We're #hiring a new Associate Director, Data Management in United States. Apply today or share this post with your network.

Today, we announced our 2025 priorities and a robust pipeline of upcoming clinical readouts including Phase 1 interim results for SPY002 and SPY003 in 2025, an indication expansion of our SPY002 program into rheumatoid arthritis, and plan to deliver four clinical proof-of-concept readouts in 2026. ? For more information, you can read the full news release and forward-looking statement legend here: https://lnkd.in/ePuZGw9X ? #IBD #RA #BioTech

We're #hiring a new Senior Manager, GMP Quality Assurance in United States. Apply today or share this post with your network.

We're #hiring a new Director, GCP Quality Assurance in United States. Apply today or share this post with your network.